These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

913 related articles for article (PubMed ID: 32252811)

  • 1. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
    Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
    Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
    Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
    Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic Breast Cancer Harboring Altered PI3K/AKT/mTOR.
    Wang R; Zhu QY; Ye WW; Huang Y; Chen ZH; Zheng YB; Zou X; Wang J; Jiang DL; Wang XJ; Xu ZY; Cao WM
    Discov Med; 2024 Mar; 36(182):527-537. PubMed ID: 38531793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
    O'Shaughnessy J; Thaddeus Beck J; Royce M
    Cancer Treat Rev; 2018 Sep; 69():204-214. PubMed ID: 30092555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
    Nagaraj G; Ma CX
    Adv Ther; 2021 Jan; 38(1):109-136. PubMed ID: 33190190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
    André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS
    Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
    Tesch H; Stoetzer O; Decker T; Kurbacher CM; Marmé F; Schneeweiss A; Mundhenke C; Distelrath A; Fasching PA; Lux MP; Lüftner D; Hadji P; Janni W; Muth M; Kreuzeder J; Quiering C; Taran FA
    Int J Cancer; 2019 Feb; 144(4):877-885. PubMed ID: 29992557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
    Campone M; Bachelot T; Gnant M; Deleu I; Rugo HS; Pistilli B; Noguchi S; Shtivelband M; Pritchard KI; Provencher L; Burris HA; Hart L; Melichar B; Hortobagyi GN; Arena F; Baselga J; Panneerselvam A; Héniquez A; El-Hashimyt M; Taran T; Sahmoud T; Piccart M
    Eur J Cancer; 2013 Aug; 49(12):2621-32. PubMed ID: 23735704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
    Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
    Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
    Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL
    Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpelisib for the treatment of
    Leenhardt F; Alexandre M; Jacot W
    Expert Opin Pharmacother; 2021 Apr; 22(6):667-675. PubMed ID: 33622114
    [No Abstract]   [Full Text] [Related]  

  • 14. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
    Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
    Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
    Pritchard KI; Burris HA; Ito Y; Rugo HS; Dakhil S; Hortobagyi GN; Campone M; Csöszi T; Baselga J; Puttawibul P; Piccart M; Heng D; Noguchi S; Srimuninnimit V; Bourgeois H; Gonzalez Martin A; Osborne K; Panneerselvam A; Taran T; Sahmoud T; Gnant M
    Clin Breast Cancer; 2013 Dec; 13(6):421-432.e8. PubMed ID: 24267730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpelisib for
    André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D;
    N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET).
    Vernieri C; Nichetti F; Lalli L; Moscetti L; Giorgi CA; Griguolo G; Marra A; Randon G; Rea CG; Ligorio F; Scagnoli S; De Angelis C; Molinelli C; Fabbri A; Ferraro E; Trapani D; Milani A; Agostinetto E; Bernocchi O; Catania G; Vantaggiato A; Palleschi M; Moretti A; Basile D; Cinausero M; Ajazi A; Castagnoli L; Lo Vullo S; Gerratana L; Puglisi F; La Verde N; Arpino G; Rocca A; Ciccarese M; Pedersini R; Fabi A; Generali D; Losurdo A; Montemurro F; Curigliano G; Del Mastro L; Michelotti A; Cortesi E; Guarneri V; Pruneri G; Mariani L; de Braud F
    Clin Cancer Res; 2021 Jun; 27(12):3443-3455. PubMed ID: 33785482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
    Bachelot T; McCool R; Duffy S; Glanville J; Varley D; Fleetwood K; Zhang J; Jerusalem G
    Breast Cancer Res Treat; 2014 Jan; 143(1):125-33. PubMed ID: 24272078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.
    Bertho M; Patsouris A; Augereau P; Robert M; Frenel JS; Blonz C; Campone M
    Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):139-152. PubMed ID: 33213227
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 46.